These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1653004)

  • 41. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use and safety of high-dose ifosfamide.
    Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946
    [No Abstract]   [Full Text] [Related]  

  • 43. [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Hartwich G; Neidhardt B; Lutz H
    Med Klin; 1978 Sep; 73(36):1247-52. PubMed ID: 692477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ifosfamide in pediatric malignancies.
    Jürgens H; Treuner J; Winkler K; Göbel U
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):46-50. PubMed ID: 2649985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of ifosfamide in small cell and non-small cell lung cancer.
    Johnson DH
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):24-30. PubMed ID: 2159187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verwey J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
    Eur J Cancer Clin Oncol; 1987 Mar; 23(3):311-21. PubMed ID: 3595691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
    Teufel G; Pfleiderer A
    Geburtshilfe Frauenheilkd; 1976 Mar; 36(3):274-9. PubMed ID: 1261795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006300. PubMed ID: 23235629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006300. PubMed ID: 20166081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ifosfamide: an old drug recently rediscovered.
    Cavalli F
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):959-61. PubMed ID: 3409945
    [No Abstract]   [Full Text] [Related]  

  • 52. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
    Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The anticancer spectrum of ifosfamide.
    Hunter HL; Harrison EF
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
    [No Abstract]   [Full Text] [Related]  

  • 54. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006300. PubMed ID: 26421585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Toxic-allergic lung edema following cyclophosphamide and ifosfamide therapy. Case report].
    Kehl A; Bergholz M; von Heyden HW; Nagel GA
    Onkologie; 1983 Apr; 6(2):84-6. PubMed ID: 6306532
    [No Abstract]   [Full Text] [Related]  

  • 56. Ifosfamide/mesa and encephalopathy.
    Cantwell BM; Harris AL
    Lancet; 1985 Mar; 1(8431):752. PubMed ID: 2858016
    [No Abstract]   [Full Text] [Related]  

  • 57. Ifosfamide in the treatment of bronchogenic carcinoma. A preliminary trial.
    Gandola L; Pozzi E; Tansini G
    G Ital Chemioter; 1978; 25(1):41-4. PubMed ID: 376387
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Morgan LR; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):56-60. PubMed ID: 6298944
    [No Abstract]   [Full Text] [Related]  

  • 59. [Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Brühl P; Hoefer-Janker H; Scheef W; Vahlensieck W
    Onkologie; 1979 Jun; 2(3):120-4. PubMed ID: 42866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Costanzi JJ; Morgan LR; Hokanson J
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):61-5. PubMed ID: 6298945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.